TACC inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
By designing and synthesizing TACC inhibitor compounds with diarylamine structures, the problem of the lack of effective TACC-targeting drugs in the prior art has been solved, providing a potential treatment option for cancers such as breast cancer, lung cancer, and colorectal cancer.
WO2026026956A1PCT designated stage Publication Date: 2026-02-05BEIJING KONRUNS PHARM CO LTD
Patent Information
- Application Number
- PCT/CN2025/112154
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-06-19
- Filing Date
- 2025-08-01
- Publication Date
- 2026-02-05
AI Technical Summary
Technical Problem
The lack of effective small molecule drugs targeting TACC in existing technologies fails to meet the market demand for cancer treatment.
Method used
Develop TACC inhibitor compounds with diarylamine structures and their pharmaceutical compositions, and prepare compounds that can target TACC through specific structural design and synthesis methods.
Benefits of technology
This provides novel small molecule drugs targeting TACC with potential anti-cancer effects, particularly for the treatment of types such as breast cancer, lung cancer, and colorectal cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2025112154_05022026_PF_FP_ABST
Abstract
Provided in the present disclosure is a compound having a diarylamine structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, which can be used as a TACC inhibitor for treating cancers.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Highly potent TACC3 inhibitor as a novel anticancer drug candidate
CN112469414A
Isoxazole derivatives targeting TACC3 as anticancer agents
CN115279754A
Compositions and methods for treating cancer
CN117460724A
Compositions and methods for treating cancer
WO2023183520A1